Literature DB >> 10409720

Bradykinin B(2) receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires dual signaling via both protein kinase C pathway and epidermal growth factor receptor transactivation.

A Adomeit1, A Graness, S Gross, K Seedorf, R Wetzker, C Liebmann.   

Abstract

The signaling routes linking G-protein-coupled receptors to mitogen-activated protein kinase (MAPK) may involve tyrosine kinases, phosphoinositide 3-kinase gamma (PI3Kgamma), and protein kinase C (PKC). To characterize the mitogenic pathway of bradykinin (BK), COS-7 cells were transiently cotransfected with the human bradykinin B(2) receptor and hemagglutinin-tagged MAPK. We demonstrate that BK-induced activation of MAPK is mediated via the alpha subunits of a G(q/11) protein. Both activation of Raf-1 and activation of MAPK in response to BK were blocked by inhibitors of PKC as well as of the epidermal growth factor (EGF) receptor. Furthermore, in PKC-depleted COS-7 cells, the effect of BK on MAPK was clearly reduced. Inhibition of PI3-Kgamma or Src kinase failed to diminish MAPK activation by BK. BK-induced translocation and overexpression of PKC isoforms as well as coexpression of inactive or constitutively active mutants of different PKC isozymes provided evidence for a role of the diacylglycerol-sensitive PKCs alpha and epsilon in BK signaling toward MAPK. In addition to PKC activation, BK also induced tyrosine phosphorylation of EGF receptor (transactivation) in COS-7 cells. Inhibition of PKC did not alter BK-induced transactivation, and blockade of EGF receptor did not affect BK-stimulated phosphatidylinositol turnover or BK-induced PKC translocation, suggesting that PKC acts neither upstream nor downstream of the EGF receptor. Comparison of the kinetics of PKC activation and EGF receptor transactivation in response to BK also suggests simultaneous rather than consecutive signaling. We conclude that in COS-7 cells, BK activates MAPK via a permanent dual signaling pathway involving the independent activation of the PKC isoforms alpha and epsilon and transactivation of the EGF receptor. The two branches of this pathway may converge at the level of the Ras-Raf complex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10409720      PMCID: PMC84372          DOI: 10.1128/MCB.19.8.5289

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  44 in total

Review 1.  Mitogenic signaling via G protein-coupled receptors.

Authors:  T van Biesen; L M Luttrell; B E Hawes; R J Lefkowitz
Journal:  Endocr Rev       Date:  1996-12       Impact factor: 19.871

2.  Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors.

Authors:  Y Wan; T Kurosaki; X Y Huang
Journal:  Nature       Date:  1996-04-11       Impact factor: 49.962

3.  Diacylglycerol generated by exogenous phospholipase C activates the mitogen-activated protein kinase pathway independent of Ras- and phorbol ester-sensitive protein kinase C: dependence on protein kinase C-zeta.

Authors:  M van Dijk; F J Muriana; P C van Der Hoeven; J de Widt; D Schaap; W H Moolenaar; W J van Blitterswijk
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

4.  Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma.

Authors:  M Lopez-Ilasaca; P Crespo; P G Pellici; J S Gutkind; R Wetzker
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

5.  Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase.

Authors:  H Cai; U Smola; V Wixler; I Eisenmann-Tappe; M T Diaz-Meco; J Moscat; U Rapp; G M Cooper
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

6.  An intact Raf zinc finger is required for optimal binding to processed Ras and for ras-dependent Raf activation in situ.

Authors:  Z Luo; B Diaz; M S Marshall; J Avruch
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

7.  Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation.

Authors:  L M Luttrell; G J Della Rocca; T van Biesen; D K Luttrell; R J Lefkowitz
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

8.  Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway.

Authors:  B E Hawes; L M Luttrell; T van Biesen; R J Lefkowitz
Journal:  J Biol Chem       Date:  1996-05-24       Impact factor: 5.157

9.  A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation.

Authors:  I Dikic; G Tokiwa; S Lev; S A Courtneidge; J Schlessinger
Journal:  Nature       Date:  1996-10-10       Impact factor: 49.962

Review 10.  Protein kinase C isozymes and substrates.

Authors:  S Jaken
Journal:  Curr Opin Cell Biol       Date:  1996-04       Impact factor: 8.382

View more
  31 in total

1.  Site-selective regulation of platelet-derived growth factor beta receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase.

Authors:  Camilla Persson; Catrine Sävenhed; Annie Bourdeau; Michel L Tremblay; Boyka Markova; Frank D Böhmer; Fawaz G Haj; Benjamin G Neel; Ari Elson; Carl-Henrik Heldin; Lars Rönnstrand; Arne Ostman; Carina Hellberg
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

2.  Mechanisms of endothelin-1-induced MAP kinase activation in adrenal glomerulosa cells.

Authors:  Bukhtiar H Shah; Albert J Baukal; Hung-Dar Chen; Ali B Shah; Kevin J Catt
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

3.  Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway.

Authors:  Delphine Mousseaux; Lionel Le Gallic; Joanne Ryan; Catherine Oiry; Didier Gagne; Jean-Alain Fehrentz; Jean-Claude Galleyrand; Jean Martinez
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

4.  Cross talk between beta-adrenergic and bradykinin B(2) receptors results in cooperative regulation of cyclic AMP accumulation and mitogen-activated protein kinase activity.

Authors:  S Hanke; B Nürnberg; D H Groll; C Liebmann
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway.

Authors:  Y Kanda; K Mizuno; Y Kuroki; Y Watanabe
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation.

Authors:  Shigeru Shibata; Juan Pablo Arroyo; María Castañeda-Bueno; Jeremy Puthumana; Junhui Zhang; Shunya Uchida; Kathryn L Stone; TuKiet T Lam; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

Review 7.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

8.  Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthase-like output of nitric oxide in inflamed endothelium.

Authors:  Jessica L Lowry; Viktor Brovkovych; Yongkang Zhang; Randal A Skidgel
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

9.  Epidermal-growth-factor receptor and metalloproteinases mediate thromboxane A2-dependent extracellular-signal-regulated kinase activation.

Authors:  Carole Gallet; Stéphanie Blaie; Sylviane Lévy-Toledano; Aïda Habib
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

10.  Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.

Authors:  Cecilea C Clayton; Michael R Bruchas; Michael L Lee; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2009-12-03       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.